Overview of insulin delivery pen devices
Lisa Kroon, PharmD, CDE
J Am Pharm Assoc (2003) 2009;49:e118-e131. doi:10.1331/JAPhA.2009.08125


Objectives  To review currently available insulin delivery pen devices for use in diabetes and to describe their primary benefits and drawbacks in comparison with the traditional vial/syringe method of insulin administration.

Data source  Not applicable.

Summary  Insulin delivery pen devices are available for most types of insulin, including all insulin analog preparations and insulin premixes with rapid-acting insulin or regular insulin with neutral protamine Hagedorn insulin. Some devices have a replaceable insulin cartridge (categorized as reusable or durable); other devices are prefilled and are disposed of after the insulin reservoir is emptied. Insulin delivery pens offer several advantages over the vial and syringe method of injection, including greater ease and discretion of use and improved portability, adherence, and dosing accuracy. The tactile and auditory feedback provided by the dosing dial on insulin delivery pen devices may be particularly helpful for patients who have impaired manual dexterity or vision. Studies also show a strong preference among patients in favor of insulin delivery pen devices compared with the vial/syringe method. Finally, despite greater per-unit cost, insulin delivery pen devices have also been associated with reductions in health resource use and associated costs compared with vial/syringe therapy.

Conclusion  Insulin delivery pen devices offer another option to patients with diabetes for insulin administration. They are associated with not only improved ease of use but also improved dosing accuracy and adherence to therapy. To develop the most suitable insulin regimens for their patients, health providers should be informed about available insulin delivery pen devices.


Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.


Register for a FREE limited account to benefit from personalization features such as alerts.


 Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Accessed at www.cdc.gov/diabetes/pubs/factsheet07.htm, July 15,  2008.
McMahon GT, Arky RA.  Inhaled insulin for diabetes mellitus. N Engl J Med. 2007;356:497–502.[PubMed][CrossRef]
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.[PubMed]
Hogan P, Dall T, Nikolov P,  American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917–32.[PubMed]
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963–72.[PubMed]
 American Diabetes Association. Standards of medical care in diabetes: 2009. Diabetes Care. 2009;32(suppl 1):S13–61.[PubMed]
 AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1–68.[PubMed]
Jellinger PS, Davidson JA, Blonde L, et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007;13:260–8.[PubMed]
Hoerger TJ, Segel JE, Gregg EW, Saaddine JB.  Is glycemic control improving in the U.S. adults? Diabetes Care. 2008;31:81–6.
Riddle MC.  The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002;18(suppl 3):S42–9.[PubMed]
Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–9.[PubMed]
Funnell MM.  Overcoming barriers to the initiation of insulin therapy. Clinical Diabetes. 2007;25:36–8.
Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27(suppl B):S89–100.[PubMed]
Costa  Da S, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ. 2002;28:52–6, 59–60.[PubMed]
Vázquez-Carrera M, Silvestre JS.  Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol. 2004;26:445–61.[PubMed]
Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;2:CD005613.[PubMed]
Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother. 2006;7:325–43.[PubMed]
Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–5.[PubMed]
Haak T, Edelman S, Walter C, et al. Comparison of usability and patient preference for the new disposable insulin device SoloS TAR versus FlexPen, Lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007;29:650–60.[PubMed]
Shelmet J, Schwartz S, Cappleman J, et al. Preference and resource utilization in elderly patients: InnoLet versus vial/syringe. Diabetes Res Clin Pract. 2004;63:27–35.[PubMed]
 American Diabetes Association. 2009 Resource Guide. Accessed at www.forecast.diabetes.org/magazine/resource-guide/insulin-and-other-injected-drugs, March 3,  2009.
Tubiana-Rufi N, Belarbi N, Pasquier-Fediaevsky  Du L, et al. Short needles (8 mm) reduce the risk of intramuscular injections in children with type 1 diabetes. Diabetes Care. 1999;22:1621–5.[PubMed]
Schwartz S, Hassman D, Shelmet J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge × 6 mm needle versus a 29 gauge × 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004;26:1663–78.[PubMed]
Solvig J, Sandahl Christiansen J, Hansen B, Lytzen L. Needle Length affects insulin deposition in normal and obese diabetes patients [abstract]. Diabetes. 2001;50(suppl 2):A132.
Asakura T, Seino H. Assessment of dose selection attributes with audible notification in insulin pen devices. Diabetes Technol Ther. 2005;7:620–6.[PubMed]
Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25:2836–48.[PubMed]
Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila). 2004;43:69–74.[PubMed]
Lteif AN, Schwenk WF.  Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care. 1999;22:137–40.[PubMed]
Graff MR, McClanahan MA.  Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20:486–96.[PubMed]
Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27:948–62.[PubMed]
Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28:1712–25.[PubMed]
Bohannon NJ, Ohannesian JP, Burdan AL, et al. Patient and physician satisfaction with the Humulin/Humalog Pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther. 2000;22:1049–67.[PubMed]
Stockl K, Ory C, Vanderplas A, et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin. 2007;23:133–46.[PubMed]
Luis  de DA, Aller R, Cuellar L, et al. Effect on quality of life with a new insulin injection device in elderly patients with diabetes mellitus type 2. J Diabetes Complications. 2004;18:216–9.[PubMed]
Pawaskar MD, Camacho FT, Anderson RT, et al. Heath care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29 Spec No:1294–305.
Kanakis SJ, Watts C, Leichter SB.  The business of insulin pumps in diabetes care: clinical and economic considerations. Clinical Diabetes. 2002;20:214–6.
 U.S. Department of Health and Human Services. Medicare.gov formulary finder for prescription drug plans: 2008. Accessed at http://formularyfinder.medicare.gov/formularyfinder/drugSelect.asp, July 15,  2008.
 Novo Nordisk. NovoLog Mix 70/30 reimbursement information: 2008. Accessed at www.novologmix70-30.com/reimbursement.asp, July 15,  2008.
Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31:430–2.[PubMed]
Santiago OM, Khutoryansky NM, Bilbo CM, et al. Accuracy and precision of the NovoPen 3 insulin delivery device after mechanical and temperature stresses. Endocr Pract. 2002;8:351–5.[PubMed]
Pellissier G, Migueres B, Tarantola A, et al. Risk of needlestick injuries by injection pens. J Hosp Infect. 2006;63:60–4.[PubMed]
Diglas J, Feinbock C, Winkler F, et al. Reduced pain perception with Pen Mate, an automatic needle insertion device for use with an insulin pen. Practical Diabetes International. 1999;16:39–41.
Dewitt DE, Hirsh IB.  Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289:2254–64.[PubMed]
Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog determir. Diabetes Care. 2005;28:1107–12.[PubMed]
 Sanofi-aventis. Opticlik. Accessed at www.opticlik.com, July 15,  2008.
 Sanofi-aventis. LANTUS SoloSTAR Pen. Accessed at www.lantus.com/solostar/solostar_insulin_pen.aspx, July 15,  2008.
 Novo Nordisk. Novo Nordisk Care. Accessed at www.novonordiskcare.com, July 15,  2008.
 Owen Mumford. Autopen. Accessed at www.owenmumford.com/en/range/6/autopen.html, July 15,  2008.
 Eli Lilly and Company. Insulin pens for the Humalog brand of insulins. Accessed at www.humalog.com/patient/humalog_insulin_pens.jsp, July 15,  2008.
 Becton, Dickinson and Company. BD Pen Needle prescribing information. Accessed at www.bddiabetes.com/us/hcp/main.aspx?cat=3067&id=3124, July 15,  2008.
Hirsch IB, Skyler JS.  The management of type 1 diabetes. In: Goldfine ID, Rushakoff RJ, Eds.  Diabetes and carbohydrate metabolism. Updated August 27, 2006. Accessed at www.endotext.org/diabetes/index.htm, July 15,  2008.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content

Customize your page view by dragging & repositioning the boxes below.

JAPhA Articles
Topic Collections
PubMed Articles
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints